Neurocrine Biosciences

Yahoo Finance • 3 days ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:(PRNewsfoto/Neurocrine Biosciences, Inc.) William Blair 46th An... Full story

Yahoo Finance • 9 days ago

A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why INGREZZA data matters for Neurocrine Biosciences stock Neurocrine Biosciences (NBIX) has drawn fresh attention af... Full story

Yahoo Finance • 11 days ago

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from a clinician survey highlighting the functional impact of INGREZZA capsules on patients with mild tardive dyskinesia (TD) at American Psychiatric As... Full story

Yahoo Finance • 24 days ago

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide choline) for the Treatment of Hyperphagia i... Full story

Yahoo Finance • 24 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Acke... Full story

Yahoo Finance • 29 days ago

Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy according to analysts. On April 22, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the first presentation of new two-year data from the Phase 3 CAHtalys... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)

BALA CYNWYD, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Earnings heat up, Fedspeak flurry, and eyes on space

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • 2 months ago

Neurocrine to acquire Soleno in $2.9bn transaction

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value. The transaction will expand Neurocrine’s portfolio in endocri... Full story

Yahoo Finance • 2 months ago

Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 Stocks With Unexpected Gains. Soleno Therapeutics soared by 32.31 percent on Monday to close at $52.25 apiece, as investors gobbled up shares following news that it is set to be acqu... Full story

Yahoo Finance • 2 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)

BALA CYNWYD, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story

Yahoo Finance • 2 months ago

Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share

Soleno Therapeutics logo Key Points Neurocrine will acquire Soleno in an all-cash tender offer at $53 per share, valuing the deal at about $2.9 billion, funded with cash on hand and not subject to a financing condition. VYKAT XR, approve... Full story

Yahoo Finance • 2 months ago

Top Midday Stories: Iran Reportedly Rejects Proposed Ceasefire; Soleno Shares Rise After $2.9 Billion Neurocrine Deal

All three major US stock indexes were edging higher in late-morning trading Monday as investors weig PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster

Neurocrine Biosciences logo 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking Neurocrine Biosciences (NASDAQ:NBIX) detailed its planned acquisition of Soleno Therapeutics on a conference call Monday, outlining the deal terms, the s... Full story

Yahoo Finance • 2 months ago

Ceasefire Prospects in Focus as US Equity Futures Trade Mixed Pre-Bell

US equity futures were mixed ahead of Monday's opening bell as traders weighed prospects for a Middl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

SLNO Jumps As Deal Buzz Lifts Stocks

This article first appeared on GuruFocus. Soleno Therapeutics (NASDAQ:SLNO) is stealing the spotlight early Monday, jumping 26% premarket as deal talks drive the biggest moves. The surge follows reports that Neurocrine Biosciences (NASDA... Full story

Yahoo Finance • 2 months ago

Nasdaq futures climb as investors weigh oil swings, jobs report exceeds expectations

Nasdaq futures climb as investors weigh oil swings, jobs report exceeds expectations Proactive uses images sourced from Shutterstock 8:10am: Oil pulls back from highs Stocks look set for a cautious but slightly upbeat open, with futures... Full story

Yahoo Finance • 2 months ago

Stocks Mostly Rise Pre-Bell as Traders Monitor Middle East War Developments

The benchmark US stock measures were mostly tracking in the green before Monday's opening bell as tr PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.

Soleno Therapeutics stock surged 40% in premarket trading Monday after Neurocrine Biosciences announced it had agreed to buy the company in a deal worth $2.9 billion. Neurocrine Biosciences said that it had agreed to buy Soleno—the maker o... Full story

Yahoo Finance • 2 months ago

Neurocrine to buy Soleno Therapeutics for $2.9 billion

April 6 (Reuters) - Neurocrine Biosciences will acquire rare disease drugmaker ‌Soleno Therapeutics for $2.9 billion in ‌cash, the companies said on Monday, marking ​the neuroscience-focused drugmaker's expansion into metabolic disorders.... Full story